Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirtobrutinib + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is an investigational chemoimmunotherapy treatment for previously untreated non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL). It integrates pirtobrutinib, a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, with the Pola-R-CHP backbone. Pola-R-CHP consists of polatuzumab vedotin (a CD79b-directed antibody-drug conjugate), rituximab (an anti-CD20 monoclonal antibody), and the chemotherapy agents cyclophosphamide, doxorubicin, and prednisone. By adding pirtobrutinib to the established Pola-R-CHP regimen, the therapy aims to enhance efficacy in the non-GCB subtype, which often relies on chronic active BCR signaling, while avoiding the cumulative neurotoxicity associated with vincristine by replacing it with polatuzumab vedotin.
- Other names
- Pirtobrutinib + Pola-R-CHPPola-R-CHP plus pirtobrutinib
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)B-cell antigen receptor complex-associated protein beta chainTOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pirtobrutinib + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirtobrutinib + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.